Although treatment outcomes have improved, relapsed or refractory chronic lymphocytic leukemia (RRCLL) is still not curable with standard therapies and has a poor prognosis. Long-term data from patients with CLL who have received chimeric antigen receptor T-cell therapy against CD19 (CART-19) are now available.
Autoren
- Birke Dikken
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Diabetes-related cardiovascular diseases
Ferroptosis: key mechanisms and novel therapeutic approaches
- Atrial fibrillation
What’s new with the “pace-and-ablate” strategy?
- De-escalation strategies
De-escalation strategies – less is more
- Pathogens in the brain
When infections trigger strokes
- Diabetes mellitus
Treatment of comorbidities in older people
- Pulmonary hypertension
PH and lung diseases
- Advanced NSCLC
MARIPOSA: Combination therapy as the new standard of care for EGFR-mutated NSCLC
- Atopic dermatitis and allergies Atopic dermatitis and allergies